Tiffany A Katz1,2, Anna H Wu3, Frank Z Stanczyk4, Renwei Wang5, Woon-Puay Koh6,7, Jian-Min Yuan5,8, Steffi Oesterreich1, Lesley M Butler9,10. 1. Department of Pharmacology and Chemical Biology, Women's Cancer Research Center, Magee Women's Research Institute, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA. 2. Department of Molecular and Cellular Biology, The Center for Precision Environmental Health, Baylor College of Medicine, Houston, TX, USA. 3. Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, USA. 4. Department of Urology, University of Southern California Keck School of Medicine, Los Angeles, CA, USA. 5. Cancer Control and Population Sciences, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA. 6. Duke-NUS Medical School, Singapore, Singapore. 7. Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore. 8. Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA. 9. Cancer Control and Population Sciences, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA. lesbutler08@gmail.com. 10. Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA. lesbutler08@gmail.com.
Abstract
PURPOSE: Mechanistic and observational data together support a role for prolactin in breast cancer development. Determinants of prolactin in Asian populations have not been meaningfully explored, despite the lower risk of breast cancer in Asian populations. METHODS: Determinants of plasma prolactin were evaluated in 442 postmenopausal women enrolled in the Singapore Chinese Health Study, a population-based prospective cohort study. At baseline all cohort members completed an in-person interview that elicited information on diet, menstrual and reproductive history, and lifestyle factors. One year after cohort initiation we began collecting blood samples. Quantified were plasma concentrations of prolactin, estrone, estradiol, testosterone, androstenedione, and sex hormone-binding globulin (SHBG). Analysis of covariance method was used for statistical analyses with age at blood draw, time since last meal, and time at blood draw as covariates. RESULTS: Mean prolactin levels were 25.1% lower with older age at menarche (p value = 0.001), and 27.6% higher with greater years between menarche and menopause (p value = 0.009). Prolactin levels were also positively associated with increased sleep duration (p value = 0.005). The independent determinants of prolactin were years from menarche to menopause, hours of sleep, and the plasma hormones estrone and SHBG (all p values < 0.01). CONCLUSION: The role of prolactin in breast cancer development may involve reproductive and lifestyle factors, such as a longer duration of menstrual cycling and sleep patterns.
PURPOSE: Mechanistic and observational data together support a role for prolactin in breast cancer development. Determinants of prolactin in Asian populations have not been meaningfully explored, despite the lower risk of breast cancer in Asian populations. METHODS: Determinants of plasma prolactin were evaluated in 442 postmenopausal women enrolled in the Singapore Chinese Health Study, a population-based prospective cohort study. At baseline all cohort members completed an in-person interview that elicited information on diet, menstrual and reproductive history, and lifestyle factors. One year after cohort initiation we began collecting blood samples. Quantified were plasma concentrations of prolactin, estrone, estradiol, testosterone, androstenedione, and sex hormone-binding globulin (SHBG). Analysis of covariance method was used for statistical analyses with age at blood draw, time since last meal, and time at blood draw as covariates. RESULTS: Mean prolactin levels were 25.1% lower with older age at menarche (p value = 0.001), and 27.6% higher with greater years between menarche and menopause (p value = 0.009). Prolactin levels were also positively associated with increased sleep duration (p value = 0.005). The independent determinants of prolactin were years from menarche to menopause, hours of sleep, and the plasma hormones estrone and SHBG (all p values < 0.01). CONCLUSION: The role of prolactin in breast cancer development may involve reproductive and lifestyle factors, such as a longer duration of menstrual cycling and sleep patterns.
Entities:
Keywords:
Breast cancer; Chinese; Hormones; Menstrual factors; Prolactin; Sleep
Authors: P Touraine; J F Martini; B Zafrani; J C Durand; F Labaille; C Malet; A Nicolas; C Trivin; M C Postel-Vinay; F Kuttenn; P A Kelly Journal: J Clin Endocrinol Metab Date: 1998-02 Impact factor: 5.958
Authors: Anna H Wu; Kazuko Arakawa; Frank Z Stanczyk; David Van Den Berg; Woon-Puay Koh; Mimi C Yu Journal: Carcinogenesis Date: 2005-01-20 Impact factor: 4.944
Authors: J M Faupel-Badger; M E Sherman; M Garcia-Closas; M M Gaudet; R T Falk; A Andaya; R M Pfeiffer; X R Yang; J Lissowska; L A Brinton; B Peplonska; B K Vonderhaar; J D Figueroa Journal: Br J Cancer Date: 2010-08-24 Impact factor: 7.640
Authors: P J Arnal; C Drogou; F Sauvet; J Regnauld; G Dispersyn; B Faraut; G Y Millet; D Leger; D Gomez-Merino; M Chennaoui Journal: J Neuroendocrinol Date: 2016-02 Impact factor: 3.627
Authors: Emily Vogtmann; Emily B Levitan; Lauren Hale; James M Shikany; Neomi A Shah; Yohannes Endeshaw; Cora E Lewis; Joann E Manson; Rowan T Chlebowski Journal: Sleep Date: 2013-10-01 Impact factor: 5.849